Table 5.

Summary of safety and effectiveness of previous publications and the current study for implantable collamer lens.

Parameter procedure	Our study	Vukich et al.	Sander et al.	Lackner	Uusitalo et al.	Fernandez et al.	Menezo et al.
Type of study	Retrospective	Prospective	Prospective	Prospective	Prospective	Retrospective	Prospective
Myopia range(D)	−4.75 to −25.25 D SE	−3.00 to −20.00 D	−3.00 to −20.00 D	−5.5 to−33.4 D	−7.75 to −29.00 D	−10 to −21.25 D	−11.5 to −28.0 D
Mean preoperative myopia	−11.70 ± 4.24 D	−10.046 D	−9.36 ± 2.66 D	−16.5 ± 5.6 D	−15.10 D	−15.27 ± 3.47 D	−16.00 ± 5.05 D
Follow-up	12.35 ± 6.13 months	16 month	12 month	24.0 ± 11.5 month	13.6 months	26.6 months ± 11.3 (SD)	18.3 months
Number of cases	69	523	210	76	38	18	21
Mean postoperative myopia	−0.69 ± 1.13 D	−0.49 ± 0.984 D	0.05 ± 0.46 D	−1.2 ± 2.0 D	−2.00 ± 2.48 D	−0.62 ± 0.81 D	−1.51 ± 1.11 D
Predictability
±0.50 D	69.8%	61.6%	76.9%	49.2%	71.1%	22.2%
±1.00 D	84.1%	84.7%	97.3%	67.7%	81.6%	56.9%	NR
±2.00 D	89%	96.7%	100%	89.2%	NR	NR
UCVA
20/40 or better	86.2%	92.5%	96%	NR	52.6%	44.4%	76.19%
20/20 or better	49.2%	60.1%	83.1%		5.3%	5.5%	0(0%)
BSCVA
20/20 or better	61.6%	82.4%	97%	NR	23.9%	NR	NR
20/40 or better	97%	98.1%	99%		63.2%
BSCVA
Loss of ⩾2lines	1(1.5%)	1(1.3%)	3(1.6%)	1(1.3%)	0(0%)	5.5%))1	0(0%)
Gain ⩾ 2 lines	13(20%)	41(9.6%)	19%))	NR	13 (40.6%)	(33.3%)	10(47.6%)

BSCVA = best spectacle-corrected visual acuity; D = diopter; SE = spherical equivalent; NR = not reported; UCVA = uncorrected visual acuity.